Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study
Ημερομηνία
2017Γλώσσα
en
Λέξη-κλειδί
Επιτομή
We describe regional differences in therapy for bloodstream infection (BSI) caused by extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-E) or carbapenemase-producing Enterobacteriaceae (CPE). Patients (n = 1482) in 12 countries from an observational study of BSI caused by ESBL-E or CPE were included. Multivariate logistic regression was used to calculate adjusted odds ratios (aORs) for the influence of country of recruitment on empirical use of β-lactam/β-lactamase inhibitors (BLBLIs) or carbapenems, targeted use of BLBLIs for ESBL-E and use of targeted combination therapy for CPE. Compared with Spain, BLBLI use for empirical therapy was least likely in sites from Israel (aOR 0.34, 95% CI 0.14–0.81), Greece (aOR 0.49, 95% CI 0.26–0.94) and Canada (aOR 0.31, 95% CI 0.11–0.88) but more likely in Italy (aOR 1.58, 95% CI 1.11–2.25) and Turkey (aOR 2.09, 95% CI 1.14–3.81). Empirical carbapenem use was more likely in sites from Taiwan (aOR 1.73, 95% CI 1.03–2.92) and USA (aOR 1.89, 95% CI 1.05–3.39) and less likely in Italy (aOR 0.44, 95% CI 0.28–0.69) and Canada (aOR 0.10, 95% CI 0.01–0.74). Targeted BLBLIs for ESBL-E was more likely in Italian sites. Treatment at sites within Israel, Taiwan, Turkey and Brazil was associated with less combination therapy for CPE. Although this study does not provide precise data on the relative prevalence of ESBL-E or CPE, significant variation in therapy exists across countries even after adjustment for patient factors. Better understanding of what influences therapeutic choices for these infections will aid antimicrobial stewardship efforts. © 2017 Elsevier B.V. and International Society of Chemotherapy
Collections
Related items
Showing items related by title, author, creator and subject.
-
Ceftazidime-avibactam to treat life-threatening infections by carbapenem-resistant pathogens in critically ill mechanically ventilated patients
Tsolaki V., Mantzarlis K., Mpakalis A., Malli E., Tsimpoukas F., Tsirogianni A., Papagiannitsis C., Zygoulis P., Papadonta M.-E., Petinaki E., Makris D., Zakynthinos E. (2020)Data on the effectiveness of ceftazidime-avibactam (CAZ-AVI) in critically ill, mechanically ventilated patients are limited. The present retrospective observational cohort study, which was conducted in two general intensive ... -
A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae
Gutiérrez-Gutiérrez B., Salamanca E., de Cueto M., Pascual A., Rodríguez-Baño J., Hsueh P.-R., Viale P., Paño-Pardo J.R., Venditti M., Tumbarello M., Daikos G., Pintado V., Doi Y., Tuon F.F., Karaiskos I., Machuca I., Schwaber M.J., Azap Ö.K., Souli M., Roilides E., Pournaras S., Akova M., Pérez F., Bonomo R.A., Bermejo J., Oliver A., Almela M., Lowman W., Almirante B., Carmeli Y., Paterson D.L., Falcone M., Russo A., Giamarellou H., Trecarichi E.M., Losito A.R., García-Vázquez E., Hernández A., Gómez J., Iosifidis E., Prim N., Navarro F., Mirelis B., Origüen J., San Juan R., Fernández-Ruiz M., Larrosa N., Puig-Asensio M., Cisneros J.M., Molina J., González V., Rucci V., Ruiz de Gopegui E., Marinescu C.I., Martínez-Martínez L., Fariñas M.C., Cano M.E., Gozalo M., Mora-Rillo M., Navarro-San Francisco C., Peña C., Gómez-Zorrilla S., Tubau F., Tsakris A., Zarkotou O., Pitout J., Virmani D., Torre-Cisneros J., Natera C., Helvaci Ö., Sahin A.O., Cantón R., Ruiz P., Bartoletti M., Giannella M., Taconelli E., Riemenschneider F., Calbo E., Badia C., Xercavins M., Gasch E., Fontanals D., Jové E. (2016)Objective To develop a score to predict mortality in patients with bloodstream infections (BSIs) due to carbapenemase-producing Enterobacteriaceae (CPE). Patients and Methods A multinational retrospective cohort study ... -
Ceftazidime/avibactam in the era of carbapenemase-producing Klebsiella pneumoniae: Experience from a national registry study
Karaiskos I., ikaraiskos@hygeia.gr, Daikos G.L., Gkoufa A., Adamis G., Stefos A., Symbardi S., Chrysos G., Filiou E., Basoulis D., Mouloudi E., Galani L., Akinosoglou K., Arvaniti K., Masgala A., Petraki M., Papadimitriou E., Galani I., Poulakou G., Routsi C., Giamarellou H. (2021)Background: Infections caused by KPC-producing Klebsiella pneumoniae (Kp) are associated with high mortality. Therefore, new treatment options are urgently required. Objectives: To assess the outcomes and predictors of ...